Introduction {#s1}
============

Anticipatory prescribing (AP) is the prescribing and dispensing of injectable medications in advance of clinical need, for visiting nurses or doctors to give as required if symptoms (pain, nausea and vomiting, agitation and respiratory tract secretions and breathlessness) arise in the final days of life.[@R1] AP may optimise symptom control for deaths in the community[@R1]: it is well established and widely recommended in the UK, New Zealand and Australia,[@R1] and less commonly in the USA, Singapore and Norway.[@R13]

The number of people dying in care homes and at home has risen dramatically during the COVID-19 pandemic in the UK and in many other countries.[@R17] AP guidance and practice has changed in response.[@R1] There is alarm about depleted drug stocks and that nurses and doctors may not be readily available to give injections.[@R5] Recent UK guidance proposed both family caregiver administration and use of different drug formulations via the buccal, rectal or sublingual routes along with traditional subcutaneous injections.[@R5]

The evidence base for current AP practice is sparse,[@R2] even more so for the buccal or sublingual routes, which are based primarily on professional experience and within paediatric palliative care.[@R13]

Family caregivers have rarely administered AP medications in the UK.[@R27] Australian experience suggests family caregivers appreciate being able to provide symptom relief: some struggle with the responsibility[@R10] and/or worry it is a form of euthanasia.[@R10] Media concerns have focused on family caregivers having a great responsibility but without adequate training or oversight.[@R20]

To support practitioners and policy-makers, we surveyed UK/Ireland professionals and investigated how AP practice has changed in response to revised national guidance and local demands during the COVID-19 pandemic.

Aims and research questions {#s1-1}
---------------------------

With regard to AP practice during the COVID-19 pandemic, what do practitioners report in relation to

1.  Changes in drug prescription?

2.  Changes in drug administration?

3.  Changes in support structures for AP?

4.  Suggestions for further changes?

Methods {#s2}
=======

An online survey (see [online supplementary appendix](#SP1){ref-type="supplementary-material"}) was developed in Survey Monkey based on the literature, our own clinical experience and SB's recent correspondence with palliative care and primary care colleagues across the UK. The study was reviewed by the University of Cambridge Psychology Research Ethics Committee (PRE.2019.013)

10.1136/bmjspcare-2020-002394.supp1

After a local pilot, an email with the survey link was sent between 8 and 13 April 2020 to delegates who attended AP workshops in 2019 for doctors, nurses and pharmacists in palliative and primary care; members of the Association for Palliative Medicine of Great Britain and Ireland, the National Institute for Health and Social Care Excellence Medicines Associate Programme and Resilient GP Facebook Group, UK Queen's Nursing Institute. Colleagues were encouraged to forward the survey link to interested colleagues, seeking a snowball sample of practitioners.[@R32]

All fields were mandatory and responses were anonymous unless respondents supplied their name and email address in the optional final field to indicate interest in a follow-up telephone interview.

Questions 1--4 sought demographic data concerning respondents' geographical areas of work, professional roles, clinical work settings and involvement in AP. Question 5 addressed changes in AP practice (if any) during the COVID-19 pandemic. These included drug types prescribed, total quantities dispensed, drug doses/ranges, drugs and support documents in home/care home, route of administration especially sublingual/buccal, persons administering AP drugs (especially family or social care colleagues), advice and support for non-clinical administration, phone or video support, prescribing in non-COVID-related illness and syringe driver use. Reasons for any changes in practice were invited in free text. Question 6 invited comments and suggestions for changes in practice, policy and legislation to optimise AP.

Data analysis {#s2-1}
-------------

The Checklist for Reporting Results of Internet E-Surveys was followed.[@R33] Descriptive statistics were used for demographic and categorical response data. For free-text replies to Questions 5 and 6, BA, BB, IW and SB developed themes inductively from the data, allocating responses to themes developed for each subquestion.[@R34] These are presented with illustrative quotations.

Results {#s3}
=======

Respondents {#s3-1}
-----------

Two hundred and sixty-one replies were received between 9 and 19 April 2020, from palliative medicine consultants (CONS 97, 37%), general practitioners (GP 63, 24%), palliative care specialist nurses (CNS 31, 12%), general community nurses (8, 7%), palliative medicine trainees (15, 6%), other doctors (12, 5%), pharmacists (5, 2%), other nurses (4, 2%) and other professional group (16, 6%). The geographical distribution of respondents is shown in [figure 1](#F1){ref-type="fig"}.

![Distribution of responders across Great Britain and Ireland.](bmjspcare-2020-002394f01){#F1}

Clinical work settings were community specialist palliative care (144, 55%), hospice inpatient unit (104, 40%), community primary care (96, 37%), hospital (87, 33%), care home (29, 11%) and other settings (7, 3%). All respondents were working clinically. Participants' involvement in the AP process were decision to prescribe (239, 92%), prescribing (225, 86%), dispensing (12, 5%), monitoring before drug administration (99, 38%), medication administration (53, 20%) and medication disposal after death (13, 5%).

Changes in AP practice {#s3-2}
----------------------

Respondents' reports of any changes in AP practice in their area, with examples from thematic analysis of the explanatory free text, are listed in [table 1](#T1){ref-type="table"}.

###### 

AP practice changes during COVID-19

  Changes to                                                                                    Yes         No          Unsure     Illustrative comment examples
  --------------------------------------------------------------------------------------------- ----------- ----------- ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Which drugs are prescribed?                                                                   98 (38%)    146 (56%)   17 (7%)    More off-licence drug use \#83 CONS.Including non-injectables, for example, buccal midazolam in case no nurse can attend \#14 CONS.Changing with availability: hyoscine patch for glycopyrronium \#253 CNS.
  The quantities of drugs prescribed?                                                           90 (35%)    137 (53%)   34 (13%)   Prescribing smaller quantities to preserve stocks \#51 CONS.Larger doses for ARDS: may need repeated sooner \#127 TRAIN.Continuing normal practice \#217 DOC.
  Drug doses/dose ranges prescribed?                                                            75 (29%)    163 (63%)   23 (9%)    Higher starting doses for distress, especially levomepromazine \#241 CONS.Up to 1-hourly if dyspnoea or distress persist \#102 CONSQuicker escalation to larger doses for some \#99 GP.Wider ranges and more prescribed to cover every eventuality \#83 CONS.
  Arrangements for drugs and supporting documents to be in the home/care home?                  96 (36%)    135 (52%)   31 (12%)   Authorisation sheet electronic \#240 GP'Grab bags\' with anticipatory meds available in emergency department \#248 CONS.Stores with army to deliver: \'just in case\' changed to \'just in time\' \#134 CONS.
  Route of administration, especially the sublingual/buccal route?                              122 (47%)   124 (48%)   15 (6%)    Oral/buccal routes give patients/relative more control without HCP \#84 CONS.Subcutaneous route first, buccal/transdermal use if availability of SC drugs affected \#64 CNS.Lorazepam, hyoscine and fentanyl patches alternatives if SC meds not available \#5 CONS.
  Person administering AP drugs, especially family/informal carers or social care colleagues?   97 (37%)    136 (52%)   28 (11%)   Family offered chance to learn if they want to \#217 DOC.Care home staff rather than district nurse after phone advice \#213 GP.Already have carer administering SC policy \#244 CONS.
  Telephone or other advice and support for AP, including family/social care administration?    127 (49%)   113 (43%)   21 (8%)    Advice line 17:00--21:00. Increased our cover on weekend and Bank Holiday \#10 CNS.Decision for AP made on FaceTime \#46 OTHER.Much more remote working now; complete change in practice \#150 GP.
  The use of phone or video to support AP practice?                                             165 (63%)   78 (30%)    18 (7%)    Care now via telephone or video including AP advice \#131 DOC.Reduces risk of transmission and aids completion of forms when patient dies \#176 GP.Video review to make decision patient is dying; may need visit in person \#240 GP.
  The prescribing of AP medications for patients with non-COVID-related illness?                63 (24%)    181 (69%)   17 (7%)    Any patient could develop COVID, anticipating higher likelihood of agitation \#71 TRAIN.Consider non injectables for non-complex \#22 CONS.Preparing for how to cope without syringe drivers \#150 GP.
  The use of syringe drivers?                                                                   79 (30%)    165 (63%)   17 (7%)    Few patients with COVID need syringe pumps as they die very quickly \#240 GP.Most dying patients with COVID easily managed by stat doses \#103 CONS.Patches due to equipment and DN resources \#39 TRAIN.

AP, anticipatory prescribing; CNS, palliative care specialist nurse; CONS, palliative medicine consultant; DN, district nurse; DOC, doctor; GP, general practitioner; HCP, health care professional; OTHER, other professional group; TRAIN, palliative medicine trainee.

Marked changes in AP were reported by about one-third in most domains. Changes in route of administration (47%) and drugs prescribed (38%) were associated with consideration of buccal, sublingual and transdermal routes and avoidance of subcutaneous injections. These related to possible administration by family or social caregivers (37%) and drug availability. Changes in quantities prescribed (35%) and doses/ranges (29%) reflected the reported needs of some dying with COVID-19 for higher doses and more frequent administration to control symptoms than previously (and to protect limited medication supplies). Changes were under way to facilitate drug delivery and relevant paperwork to the home (36%).

At the same time, clinical contact and patient assessment were changing to telephone or video rather than in person (63%). Telephone advice was more available (49%). Changes in prescribing for non-COVID-19 terminal illness (24%) reflected moves towards non-injectable routes and concern that they might develop COVID-19 and associated severe agitation. Planned reductions in syringe driver use (30%) reflected perceptions that the COVID-19 terminal phase is brief and best managed with 'as needed' individual doses and that both district nurses and syringe drivers might be in short supply.

Practitioners' comments and suggestions for change {#s3-3}
--------------------------------------------------

The dominant themes were calls for three changes in pharmaceutical legislation.

### Permit repurposing of prescribed AP drugs in care homes {#s3-3-1}

Allowing care homes to re-use AP medications when the patient has died and the drugs have not been used. Such a waste of meds. \#209 CONS

COVID outbreak in nursing home we care for. Would be very useful if could re-use Anticipatory subcutaneous medications and also if the nursing home could hold a small supply. \#227 GP

### Enable wider ready access to drugs in the community {#s3-3-2}

Nursing homes have asked for spare sets of anticipatory medications should patients unexpectedly become unwell, but this is not within the law. \#142 GP

It would be really helpful to have a centralised stock of AP drugs (maybe with community nursing teams) so that each patient just has what they need dispensed when they need it. \#170 GP

Having access 24 hours for anticipatory meds: prescription and meds in key localities to enable rapid response and symptom control. \#119 CNS

### Permit recycling of drugs returned to pharmacies {#s3-3-3}

Enable unused vials to be taken back to pharmacy and reused. Fear of waste and cost are factors that limit the amount of AP in the community. \#245 CONS

This is our opportunity to secure legislative change for the establishment of centralised supplies, the ability for clinical staff to have sensible safe boxes and for the return of safe, unused drugs to pharmacies ... This is a known and appalling waste that must stop now and be permanent. There has never been a cogent justification. \#100 CONS

Discussion {#s4}
==========

This study revealed rapid change in AP practice is under consideration in many areas of the UK/Ireland: increased use of alternative routes, changes in drugs prescribed to address stock shortages, new routes of administration, family caregiver administration; later prescribing of AP drugs and smaller quantities. There were calls to new pharmaceutical regulations to permit repurposing of AP medications in care homes, wider community drug access and recycling unused medications returned to pharmacies. Reflecting broader changes in community end-of-life-care during the pandemic, more end-of-life care in general and AP in particular is undertaken remotely and electronically, with increased 24 hours availability. These changes will potentially significantly affect care during the pandemic and in the future.

The main strengths of this study were the large number of responses, the broad distribution of replies from across the UK and Ireland and the contemporaneous data. Anonymity encouraged candid responses. It is not possible to calculate a response rate due to the snowball sampling.

Major changes are under way in routes of AP drug administration; community adult end-of-life care practice is increasingly accepting the buccal and sublingual routes. Robust evidence is urgently needed about their pharmacokinetics to develop evidence-based guidelines on suitable drugs, preparations and doses which is currently based largely on clinical experience in paediatric palliative care. While transdermal administration is well established, it lacks the flexibility and rapidity of relief when symptoms are unstable in the dying.[@R27] This is particularly important for those dying from COVID-19 in whom there is a need for higher drug doses and more frequent administration for effective symptom control.

Many areas are adopting proposals in national policies to consider caregiver drug administration.[@R35] This is a big ask for family caregivers with significant risks for their psychological welfare. They may feel pressure to undertake clinical tasks; responsibility for medications heightens anxieties during an already emotional time.[@R10] Nurses often worry about oversedating patients or accelerating death when they give end-of-life medications.[@R3] Should a patient die shortly after family caregivers give a medication, they may have even greater concerns.[@R10] Clinicians must be careful whom they approach to undertake these tasks, discuss alternative care options and ensure appropriate training and support is available for willing family caregivers.[@R6] After death, family caregivers confront these worries while being isolated in their grief during the pandemic.[@R19]

Many palliative care services have responded to the pandemic with extended availability of telephone advice for clinical and social care colleagues, often now including patients and family members. These are welcome developments. The move of much community palliative care to remote video or telephone consultations is understandable due to the need to avoid infection risk to patient, family and clinician. However, this change risks impairing the quality of communication and clinical assessments involved. Video diagnosis of the dying phase and AP decisions, reported by participants, require remote consultation skills that may be more familiar to general practitioners than some working in palliative care services.

Pharmaceutical regulations and policies pertaining to AP in care homes arise from legitimate needs to protect residents from drug errors, particularly with controlled drugs like morphine and midazolam.[@R38] The presence of suitable medications already in the homes, prescribed for one resident but then urgently needed for another, is frustrating for care home staff and visiting clinicians, as until recently they have been unable to repurpose drugs. Recent UK guidance, issued on 28 April 2020, now permits repurposing in care homes and hospices: this welcome development, called for by many participants, was introduced after data collection was complete.[@R40] The related regulations requiring destruction of medications after death and on return to a pharmacy is as yet unresolved.[@R39] These tensions are not new but more acute during the pandemic when many care home residents are at risk of dying from COVID-19 and drugs may be in short supply.[@R5] A focus on preserving limited drug stocks may delay AP until an individual is close to the end of their life, but risks undermining ready drug availability, which is the essence of AP.

Respondents reported that some dying from COVID-19 have a relatively brief dying phase requiring larger than usual drug doses. This makes current guidance to prescribe drugs in small amounts and close to anticipated death problematic. Community clinicians are conflicted. Wider and more ready community drug access might ease this difficulty but presents legislative and logistical challenges.[@R19]

Conclusions {#s5}
===========

The COVID-19 pandemic is a challenge to community palliative care. It creates opportunities to innovate rapidly and learn from paediatric palliative care. Given the risk from face-to-face consultations and visits for drug administration, care is now more virtual and remote, with greater dependence on family caregivers to provide care and administer drugs, often via non-injectable routes. These changes are occurring at pace: it remains to be seen how widely they are implemented, how effective they are and how much they will persist after the pandemic. We would welcome collaborations with colleagues across the world to address these important questions.
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